In the great state of Tennessee, there is a company that is on the cutting edge of cancer research and has taken their technology worldwide in an attempt to help cure the disease. The company is Provectus Pharmaceuticals and if they achieve continued success, they may soon be a well known name.

Provectus Pharmaceuticals is a development-stage oncology and dermatology biopharmaceutical company which uses the agent PV-10 as a therapeutic agent for a broad spectrum of cancers. Currently, PV-10 is available for select cancer patients in the U.S. but the program was initiated in Australia in June of 2009 and has excelled across the globe.

In the U.S., the PV-10 program commenced at St. Luke’s Hospital and Health Network in Bethlehem, PA under the watchful eye of the renowned Dr. Sanjiv Agarwaia who served as the Principal Investigator at that site for the Phase 2 Melanoma Trial. The U.S.

Provectus Pharmaceuticals Inc. (PVCT.OB) is a Tennessee-based development stage pharmaceutical company that specializes in oncology and dermatology therapies. Complementing the company’s lineup of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.

In the biotechnology area, the company has developed groundbreaking technology to augment vaccine production and detect viruses. Another area that Provectus is focusing on is the dermatology space. The company is currently conducting Phase 2 clinical trials of their proprietary drug PH-10, to be used as a topical treatment for psoriasis and atopic dermatitis.

Provectus Pharma’s main focus however is in the treatment of cancer. The company is developing advanced therapies to target and destroy the deadliest cancers - melanoma, liver cancer, and breast cancer - while eliminating side effects. Clinical trials for treatment of metastatic melanoma and recurrent breast carcinoma with the company’s PV-10 drug are